Your browser doesn't support javascript.
loading
Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce.
Willis, Zachary I; Oliveira, Carlos R; Abzug, Mark J; Anosike, Brenda I; Ardura, Monica I; Bio, Laura L; Boguniewicz, Juri; Chiotos, Kathleen; Downes, Kevin; Grapentine, Steven P; Hersh, Adam L; Heston, Sarah M; Hijano, Diego R; Huskins, W Charles; James, Scott H; Jones, Sarah; Lockowitz, Christine R; Lloyd, Elizabeth C; MacBrayne, Christine; Maron, Gabriela M; Hayes McDonough, Molly; Miller, Christine M; Morton, Theodore H; Olivero, Rosemary M; Orscheln, Rachel C; Schwenk, Hayden T; Singh, Prachi; Soma, Vijaya L; Sue, Paul K; Vora, Surabhi B; Nakamura, Mari M; Wolf, Joshua.
Afiliación
  • Willis ZI; Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • Oliveira CR; Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA.
  • Abzug MJ; Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.
  • Anosike BI; Department of Pediatrics, The Children's Hospital at Montefiore and Albert Einstein College of Medicine, Bronx, NY, USA.
  • Ardura MI; Department of Pediatrics, ID Host Defense Program, Nationwide Children's Hospital & The Ohio State University, Columbus, OH, USA.
  • Bio LL; Department of Pharmacy, Lucile Packard Children's Hospital, Stanford, CA, USA.
  • Boguniewicz J; Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.
  • Chiotos K; Departments of Anesthesiology, Critical Care Medicine, and Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Divisions of Critical Care Medicine and Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Downes K; Department of Pediatrics, Perelman School of Medicine of the University of Pennsylvania, Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Grapentine SP; Department of Pharmacy, University of California San Francisco Benioff Children's Hospital, San Francisco, CA, USA.
  • Hersh AL; Department of Pediatrics, Division of Infectious Diseases, University of Utah, Salt Lake City, UT, USA.
  • Heston SM; Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
  • Hijano DR; Department of Infectious Diseases, St. Jude Children's Research Hospital and Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA.
  • Huskins WC; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
  • James SH; Department of Pediatrics, Division of Pediatric Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Jones S; Department of Pharmacy, Boston Children's Hospital, Boston, MA, USA.
  • Lockowitz CR; Department of Pharmacy, St. Louis Children's Hospital, St. Louis, Missouri, USA.
  • Lloyd EC; Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
  • MacBrayne C; Department of Pharmacy, Children's Hospital Colorado, Aurora, CO, USA.
  • Maron GM; Department of Infectious Diseases, St. Jude Children's Research Hospital and Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA.
  • Hayes McDonough M; Center for Healthcare Quality & Analytics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Miller CM; Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA.
  • Morton TH; Department of Pharmacy, St Jude's Children's Research Hospital, Memphis, Tennessee, USA.
  • Olivero RM; Department of Pediatrics and Human Development, Michigan State College of Human Medicine and Helen DeVos Children's Hospital of Corewell Health, Grand Rapids, MI, USA.
  • Orscheln RC; Department of Pediatrics, Washington University, St. Louis, MO, USA.
  • Schwenk HT; Department of Pediatrics, Stanford School of Medicine, Stanford, CA, USA.
  • Singh P; Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
  • Soma VL; Department of Pediatrics, NYU Grossman School of Medicine, New York, NY, USA.
  • Sue PK; Department of Pediatrics, Columbia University, New York, NY, USA.
  • Vora SB; Department of Pediatrics, University of Washington School of Medicine, and Division of Infectious Diseases, Seattle Children's Hospital, Seattle, WA, USA.
  • Nakamura MM; Antimicrobial Stewardship Program and Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
  • Wolf J; Department of Infectious Diseases, St. Jude Children's Research Hospital and Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA.
J Pediatric Infect Dis Soc ; 13(3): 159-185, 2024 Mar 19.
Article en En | MEDLINE | ID: mdl-38339996
ABSTRACT

BACKGROUND:

Since November 2019, the SARS-CoV-2 pandemic has created challenges for preventing and managing COVID-19 in children and adolescents. Most research to develop new therapeutic interventions or to repurpose existing ones has been undertaken in adults, and although most cases of infection in pediatric populations are mild, there have been many cases of critical and fatal infection. Understanding the risk factors for severe illness and the evidence for safety, efficacy, and effectiveness of therapies for COVID-19 in children is necessary to optimize therapy.

METHODS:

A panel of experts in pediatric infectious diseases, pediatric infectious diseases pharmacology, and pediatric intensive care medicine from 21 geographically diverse North American institutions was re-convened. Through a series of teleconferences and web-based surveys and a systematic review with meta-analysis of data for risk factors, a guidance statement comprising a series of recommendations for risk stratification, treatment, and prevention of COVID-19 was developed and refined based on expert consensus.

RESULTS:

There are identifiable clinical characteristics that enable risk stratification for patients at risk for severe COVID-19. These risk factors can be used to guide the treatment of hospitalized and non-hospitalized children and adolescents with COVID-19 and to guide preventative therapy where options remain available.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Guideline / Prognostic_studies / Qualitative_research / Risk_factors_studies Límite: Adolescent / Child / Humans Idioma: En Revista: J Pediatric Infect Dis Soc Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Guideline / Prognostic_studies / Qualitative_research / Risk_factors_studies Límite: Adolescent / Child / Humans Idioma: En Revista: J Pediatric Infect Dis Soc Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido